Maximize Your Portfolio with Data Driven Insights:
- Leverage the power of TipRanks' Smart Score, a data-driven tool to help you uncover top performing stocks and make informed investment decisions.
- Monitor your stock picks and compare them to top Wall Street Analysts' recommendations with Your Smart Portfolio
The latest update is out from Prelude Therapeutics ( (PRLD) ).
Prelude Therapeutics has appointed Bryant D. Lim as the permanent Chief Financial Officer, effective February 3, 2025, while he continues his roles as Chief Legal Officer and Corporate Secretary. This decision follows his interim CFO position, and his employment agreement includes a base salary, bonus eligibility, stock options, and benefits contingent upon his continued service and compliance with the agreement.
More about Prelude Therapeutics
YTD Price Performance: -11.20%
Average Trading Volume: 452,252
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $61.09M
Find detailed analytics on PRLD stock on TipRanks’ Stock Analysis page.
